



K COVID₁₉; SARS-C V_2 ; Asymptomatic patient; Physical exercise; Good nutrition

I ⁴c

e rst scienti c study describing C a (HC V - human C a) as a disease promoter human was released in the 1960s, although, the virus was initially founded in Ga a d e c birds in 1930 [1]. Currently, coronaviruses are classi ed in the order N d a e, subfamily O c a ae and subdivided in four genus: A ac a (-C V), Be ac a (-C V) and some members belonging to Ga ac a (-C V) are pathogens to mammalian, although some strains belonging to genus -C V and De ac a (-C V) have adapted to cause disease in avian. Among the viral strains classi ed as HC V, the following stand out: -HC V_{229E}, -HC V_{NL63}, -HC V_{OC43}, -HC V_{HKU1}, -MERS-C V, -SARS-C V and -SARS-C V₂.

e strains -HC V_{229E} and -HC V_{0C43} rst identi ed in the mid-1960s [1-3], are closely related with the common cold syndrome and pneumonia [4-8], uncommonly causing severe diseases. It was also reported that both strains can cause LRTI (Lower Respiratory Tract Infections) and otitis media [3]. Often this virus is detected in co-infections with other strains of viruses and bacteria resulting respiratory infections [4,9-11]. In addition, this virus also is widely distribution worldwide with seasonal outbreaks [12]. HC V infections have been described for decades, occurring in 2- to 3-year cycles [13], with seasons of high infections rates caused by strains -HC V_{229E} or

-HC V_{OC43} and sporadic infections caused by strains belonging to the others HC V groups [12].

e strain -HC $V_{\rm NL63}$ was reported for the rst time in 2004 in a baby from Netherlands suffering from bronchiolitis [11,14]. However, this strain seems to affect mostly immunocompromised children inducing symptoms as cough, fever, and rhinorrhea or severe LRTI,

*Corresponding author: José Ednésio da Cruz Freire, Federal University of Ceará, Brazil, Tel:+85989053509; E-mail: jednesio@gmail.com

Received September 03, 2020; Accepted September 22, 2020; Published September 29, 2020

Citation: Freire JEC, Fonseca FMP, Freire CMAS, Rocha LLS (2020) SARS-*CoV₂*: A Brief Analysis of the History of an Asymptomatic Patient. Occup Med Health Aff 8: 323.

Copyright: © 2020 Freire JEC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

may be due to the cytopathic effect mediated by local replication of the SARS-*C* V; or indirectly as a result of systemic responses to respiratory failure or the harmful immune response induced by viral infection.

In 2012, the outbreak of a new C V capable of causing Middle East respiratory syndrome (MERS-C V) was reported, being the rst case occurred in Kingdom of Saudi Arabia (KSA), recording at least 2468 cases and 851 deaths worldwide [19]. Another well-documented case of MERS-C V occurred in May 2015, according to information from Korea Centers for Disease Control and Prevention (2015), an infected individual returning from the Middle East started the outbreak of MERS-C V in South Korea, which spread over 16 hospitals and 186 patients. On the next year, were reported 1,728 con rmed new cases of MERS-C V, and 624 deaths were noti ed in 27 countries [20]. In 2018 a new outbreak of MERS-C V was recorded in the Saudi Arabia [21], with 96 new cases. After these outbreaks of MERS-C V, very year's new cases are documented, usually associated with infected travels; often, these imported MERS cases resulted in nosocomial transmission [19]. Symptoms of MERS-C V are fever, cough and upper respiratory tract (URT) signs and symptoms usually occur rst, followed within a week by progressive LRT distress and lymphopenia[22].

e current pandemic of COVID₁₉ (*CO*rona*VI*rus*D*isease and 19 refers to year 2019, was rst reported at Wuhan, China. e clinical manifestations are very similar to SARS-C V infection (for that reason it was described as SARS-C V_2). Elderly population stands out as the group with the highest risk, especially those that feature previous comorbidities [23]. In addition, Jordan and collaborators (2020), reported that the restrictions imposed as a control measure during SARS-C V_2 pandemic, may lead elderly people to experience loneliness, isolation and loss of mental and physical stimulation, which could increase the severity of infection.

G ccaac c CoV

C Vs are featured by a positive single-stranded RNA. At the molecular level, C Vs usually feature high mutation rate due to the propensity of errors during their replication [23-25]. It has been shown that these viruses naturally present 20% homologous RNAs recombination mixed infections with different viral strains the same group [23].

Genetic recombination and point mutations in the genome of C Vs can be considered as mechanisms of adaptation between strains, since it is speculated that HC V_{NL63} has arisen from the evolution of HC V_{229E} [26]. In 2018, Chinese scientists reported a new genotype of strain HC V_{OC43} , named H by Zhu and collaborators (2018). It is possible that the H strain emerged as a result after genetic recombination involving seven other stains of HC V_{OC43} [27], previously identi ed as HC V_{OC43}^{a} - HC V_{OC43}^{s} . In 2006 was described the circulation of HC V_{HKU1} strain throughout the United States, however, with genetic differences from the stain originally identi ed in Hong Kong, revealing the easy adaptation of C V strains to different environmental and climatic conditions [28].

Scienti c approaches involving c simulation have been useful to address may hypotheses. In 2006, a prospective study developed by [29], using c predictions, analyzed 25 variants of HC $V_{\rm 229E}$ disseminated in Australia, described during the years of 1979 to 2004. In the study, gene product S and N (spike protein and nucleoprotein) were selected, considering them primary role of facilitates the virus binding to the host cell. In this research the authors concluded that S protein has not mutated over the years, therefore, a type of positive selection mechanism exists, and probably are one of the mechanisms

responsible for the emergence of new viral strains [29]. ese results were corroborated by Li and collaborators (201.lqn considering them

Citation: Freire JEC, Fonseca FMP, Freire CMAS, Rocha LLS (2020) SARS-CoV₂: A Brief Analysis of the History of an Asymptomatic Patient. Occup Med Health Aff 8: 323.

R a⁴⁴ c

Citation: Freire JEC, Fonseca FMP, Freire CMAS, Rocha LLS (2020) SARS-CoV₂: A Brief Analysis of the History of an Asymptomatic Patient. Occup Med Health Aff 8: 323.

Page 4 of 6

			1
Test	Results	Method	Reference value
Triglycerides	263 mg/dL	Enzymatic	< 150 mg/dL
Total cholesterol	218 mg/dL	Direct enzymatic	< 200 mg/dL
HDL	48.5 mg/dl	Colorimetric without precipitation	23-92 mg/dl
LDL	106.0 mg/dL	Direct enzymatic	< 130 mg/dL
VLDL	52.6 mg/dL	Calculation	< 40 mg/dL
Glucose	88 mg/dL	Enzymatic	70 – 99 mg/dL
Vitamin D	27.7 ng/mL	Chemiluminescence – LIAISON DiaSorin	
Vitamin B12	566 pg/mL	immunoassay – Immulite 2000 XPI – Siemens	193 – 982 pg/mL
Calcium	7.8 mg/dL	Colorimetric	8.6 – 10.3 mg/dL
Magnesium	2.2 mg/dL	Colorimetric	1.9 – 2.7 mg/dL
Urea	31 mg/dL	Kinetics	15 – 43 mg/dL
Creatinine	0.9 mg/dL	Colorimetric	0.6 – 1.3 mg/dL
Alkaline phosphatase	59 U/L	Enzymatic	34 – 104 U/L
GGT	62 U/L	Colorimetric	9 – 64 U/L
TGO	22 U/L	Enzymatic	13 – 39 U/L
TGP	30 U/L	Enzymatic	7 – 52 U/L
Serum phosphorus	3.5 mg/dL	Colorimetric	2.5 – 5 mg/dL
Chlorine	106 mEq/L	Colorimetric	98 – 107 mEq/L
Sodium	139 mEq/L	Colorimetric	136 – 145 mEq/L
Potassium	4.4 mEq/L	Colorimetric	3.5 – 5.1 mEq/L
TSH	1.030 µIU/mL	Microparticle chemiluminescent immunoassay - Immulite - Siemens	1.01 ng/dL
Free thyroxine (T4)	1.01 ng/dL	Microparticle chemiluminescent immunoassay - Immulite - Siemens	2000 XPI 0.89 – 1.79 ng/dL

Table 1: Laboratory tests requested for Biochemical analysis, method used for diagnosis and reference values adopted at the Hospital Geral Dr. César Cals, Fortaleza-CE.

Citation: Freire JEC, Fonseca FMP, Freire CMAS, Rocha LLS (2020) SARS-CoV₂: A Brief Analysis of the History of an Asymptomatic Patient. Occup Med Health Aff 8: 323.

Page 5 of 6

- Pene F, Merlat A, Vabret A, Rozenberg F, Buzyn A (2003) Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infec Dis 37:929-932.
- Vabret A, Mourez T, Gouarin S, Petitjean J, Freymuth F (2003) An outbreak of Coronavirus OC43 respiratory infection in Normandy, France. Clini Infect Dis 36:985-989.
- Pfefferle S, Oppong S, Drexler JF, Gloza-Rausch F, Ipsen A, et al. (2009) Distant relatives of severe acute respiratory syndrome Coronavirus and close relatives of human Coronavirus 229E in bats, Ghana. Emerg Infec Dis 15:1377-1384.
- Vassilara F, Spyridaki A, Pothitos G, Deliveliotou A, Papadopoulos A (2018) A Rare case of human Coronavirus 229E associated with acute respiratory distress syndrome in a healthy adult. Hindawi 6796839:1-4.
- Golda A, Malek N, Dudek B, Zeglen S, Wojarski J, et al. (2011) Infection with human Coronavirus NL63 enhances streptococcal adherence to epithelial cells. J Gen Virol 92:1358-1368.
- 10. Zhao M, Li G, Zhang D, Zhou H, Wang H, et al. (2017) Clinical evaluation of a new single-tube multiplex reverse transcription PCR assay for simultaneous detection of 11 respiratory viruses, Mycoplasma pneumoniae and Chlamydia in hospitalized children with acute respiratory infections. Diag Microbiol Infect Dis 88:115-119.
- 11. Liu DX, Liang JQ, Fung TS (2020) Human Coronavirus-229E, -OC43, -NL63, and -HKU1. Ref Mod Life Sci 1-13.

12.

Page 6 of 6

- 50. Korea Centers for Disease Control and Prevention (2015) Middle East respiratory syndrome Coronavirus outbreak in the Republic of Korea, 2015. Osong Pub Health Res Persp 6:269-278.
- Li Z, Tomlinson ACA, Wong AHM, Zhou D, Desforges M, et al. (2019) The human Coronavirus HCoV-229E S-protein structure and receptor binding. eLIFE 8:e51230.
- 52. Kizilbash SJ, Ahrens SP, Bruce BK, Chelimsky G, Driscoll SW, et al. (2014) Adolescent Fatigue, POTS, and Recovery: A Guide for Clinicians. Curr Prob Pediat Adol Health Care 44:108-133.
- 53. Woo P, Lau S, Yip C, Huang Y, Yuen KY, et al. (2009) More and more Coronaviruses: Human Coronavirus HKU1. Viruses 1:57-71.
- 54. Pan Y, Li X, Yang G, Fan J, Tang Y, et al. (2020) Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect 81:e28-e32.
- 55. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, et al. (2020) Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: A modeling study. Lancet Glob Health 8: e1003-e1017.
- Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, et al. (2004) Characterization of severe acute respiratory syndrome-associated Coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. PNAS 101:4240-4245.